Matrix Asset Advisors is urging Genzyme's board to replace Henri Termeer as CEO and accept activist-investor Carl Icahn's board nominees, two of whom are directors at Biogen Idec, a major manufacturer of multiple sclerosis drugs. However, recent tests showing that Genzyme's blood cancer drug Campath is effective in patients with MS could threaten Icahn's proxy challenge.

Full Story:
Boston Herald

Related Summaries